M E Levy1, A E Greenberg1, R Hart2, L Powers Happ1, C Hadigan3, A Castel1. 1. Department of Epidemiology and Biostatistics, Milken Institute School of Public Health at the George Washington University, Washington, DC, USA. 2. Research Department, Cerner Corporation, Kansas City, MO, USA. 3. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Abstract
OBJECTIVES: With the increasing impact of cardiovascular disease among populations aging with HIV, contemporary prevalence estimates for predisposing metabolic comorbidities will be important for guiding the provision of relevant lifestyle and pharmacological interventions. We estimated the citywide prevalence of hypertension, type 2 diabetes, dyslipidaemia, and obesity; examined differences by demographic subgroups; and assessed clinical correlates. METHODS: Utilizing an electronic medical record (EMR) database from the DC Cohort study - a multicentre prospective cohort study of HIV-infected outpatients - we assessed the period prevalence of metabolic comorbidities between 2011 and 2015 using composite definitions that incorporated diagnoses, pharmacy records, and clinical/laboratory results. RESULTS: Of 7018 adult patients (median age 50 years; 77% black), 50% [95% confidence interval (CI) 49-51] had hypertension, 13% (95% CI: 12-14) had diabetes, 48% (95% CI: 47-49) had dyslipidaemia, and 35% (95% CI: 34-36) had obesity. Hypertension was more prevalent among black patients, diabetes and obesity were more prevalent among female and black patients, dyslipidaemia was more prevalent among male and white patients, and comorbidities were more prevalent among older patients (all P < 0.001). For many patients, evidence of treatment for these comorbidities was not available in the EMR. Longer time since HIV diagnosis, greater duration of antiretroviral treatment, and having controlled immunovirological parameters were associated with metabolic comorbidities. CONCLUSIONS: These findings underscore the pervasive burden of metabolic comorbidities among HIV-infected persons, serve as the basis for future analyses characterizing their impact on subsequent adverse cardiovascular outcomes, and highlight the need for an increased focus on the prevention and control of comorbid complications in this population.
OBJECTIVES: With the increasing impact of cardiovascular disease among populations aging with HIV, contemporary prevalence estimates for predisposing metabolic comorbidities will be important for guiding the provision of relevant lifestyle and pharmacological interventions. We estimated the citywide prevalence of hypertension, type 2 diabetes, dyslipidaemia, and obesity; examined differences by demographic subgroups; and assessed clinical correlates. METHODS: Utilizing an electronic medical record (EMR) database from the DC Cohort study - a multicentre prospective cohort study of HIV-infected outpatients - we assessed the period prevalence of metabolic comorbidities between 2011 and 2015 using composite definitions that incorporated diagnoses, pharmacy records, and clinical/laboratory results. RESULTS: Of 7018 adult patients (median age 50 years; 77% black), 50% [95% confidence interval (CI) 49-51] had hypertension, 13% (95% CI: 12-14) had diabetes, 48% (95% CI: 47-49) had dyslipidaemia, and 35% (95% CI: 34-36) had obesity. Hypertension was more prevalent among black patients, diabetes and obesity were more prevalent among female and black patients, dyslipidaemia was more prevalent among male and whitepatients, and comorbidities were more prevalent among older patients (all P < 0.001). For many patients, evidence of treatment for these comorbidities was not available in the EMR. Longer time since HIV diagnosis, greater duration of antiretroviral treatment, and having controlled immunovirological parameters were associated with metabolic comorbidities. CONCLUSIONS: These findings underscore the pervasive burden of metabolic comorbidities among HIV-infectedpersons, serve as the basis for future analyses characterizing their impact on subsequent adverse cardiovascular outcomes, and highlight the need for an increased focus on the prevention and control of comorbid complications in this population.
Authors: Vicente Estrada; José Ignacio Bernardino; Mar Masiá; José Antonio Iribarren; Alejandra Ortega; Fernando Lozano; Celia Miralles; Julián Olalla; Jesús Santos; María Jesús Pérez Elías; Pere Domingo; Arturo Fernández Cruz Journal: HIV Clin Trials Date: 2015-01-22
Authors: T R Glass; C Ungsedhapand; M Wolbers; R Weber; P L Vernazza; M Rickenbach; H Furrer; E Bernasconi; M Cavassini; B Hirschel; M Battegay; H C Bucher Journal: HIV Med Date: 2006-09 Impact factor: 3.180
Authors: Matthew S Freiberg; Kathleen A McGinnis; Kevin Kraemer; Jeffrey H Samet; Joseph Conigliaro; R Curtis Ellison; Kendall Bryant; Lewis H Kuller; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2010-02 Impact factor: 3.731
Authors: Kristina Crothers; Joseph L Goulet; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Matthew Bidwell Goetz; Stephen Crystal; David A Leaf; Adeel A Butt; R Scott Braithwaite; Robin Peck; Amy C Justice Journal: AIDS Educ Prev Date: 2009-06
Authors: Matthew J Feinstein; Ehete Bahiru; Chad Achenbach; Christopher T Longenecker; Priscilla Hsue; Kaku So-Armah; Matthew S Freiberg; Donald M Lloyd-Jones Journal: Am J Cardiol Date: 2015-11-06 Impact factor: 2.778
Authors: E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923
Authors: Ingjerd W Manner; Marius Trøseid; Olav Oektedalen; Morten Baekken; Ingrid Os Journal: J Clin Hypertens (Greenwich) Date: 2012-10-26 Impact factor: 3.738
Authors: Julie A Ake; Christina S Polyak; Trevor A Crowell; Francis Kiweewa; Michael Semwogerere; Lucas Maganga; Emmanuel Bahemana; Jonah Maswai; Rither Langat; John Owuoth; Solomon Otieno; Babajide Keshinro; Allahna L Esber; Michelle Liu; Leigh Anne Eller; Kavitha Ganesan; Ajay P Parikh; Tiffany E Hamm; Merlin L Robb; Patrick W Hickey; Victor G Valcour; Nelson L Michael Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel Journal: AIDS Res Hum Retroviruses Date: 2018-11-27 Impact factor: 2.205
Authors: Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: David E Wallace; Michael A Horberg; Debra A Benator; Alan E Greenberg; Amanda D Castel; Anne K Monroe; Lindsey Powers Happ Journal: AIDS Care Date: 2020-08-18
Authors: Lindsey Powers Happ; Anne K Monroe; Heather A Young; Yan Ma; Alan E Greenberg; Michael A Horberg; Amanda D Castel Journal: J Acquir Immune Defic Syndr Date: 2020-09-01 Impact factor: 3.731
Authors: R C Basil; T T Brown; S Haberlen; L H Rubin; M Plankey; J T Becker; J E Lake; F J Palella; S Sarkar Journal: HIV Med Date: 2020-09-24 Impact factor: 3.180